25 XP   0   0   10

Werewolf Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Werewolf Therapeutics Inc together

PenkeI guess you are interested in Werewolf Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Werewolf Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Werewolf Therapeutics Inc

I send you an email if I find something interesting about Werewolf Therapeutics Inc.

Quick analysis of Werewolf Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Werewolf Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.61
Expected worth in 1 year
$2.35
How sure are you?
23.1%

+ What do you gain per year?

Total Gains per Share
$-0.26
Return On Investment
-4.3%

For what price can you sell your share?

Current Price per Share
$5.90
Expected price per share
$3.35 - $8.1939
How sure are you?
50%

1. Valuation of Werewolf Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$5.90

Intrinsic Value Per Share

$-5.75 - $-6.52

Total Value Per Share

$-3.15 - $-3.91

2. Growth of Werewolf Therapeutics Inc (5 min.)




Is Werewolf Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$111.3m$130.6m$646.7k0.5%

How much money is Werewolf Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$9.1m-$12.8m$3.7m40.5%
Net Profit Margin-314.2%-179.4%--

How much money comes from the company's main activities?

3. Financial Health of Werewolf Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#357 / 1016

Most Revenue
#360 / 1016

Most Profit
#538 / 1016

Most Efficient
#694 / 1016

What can you expect buying and holding a share of Werewolf Therapeutics Inc? (5 min.)

Welcome investor! Werewolf Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Werewolf Therapeutics Inc.

What can you expect buying and holding a share of Werewolf Therapeutics Inc?

First you should know what it really means to hold a share of Werewolf Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Werewolf Therapeutics Inc is $5.9. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Werewolf Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Werewolf Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.61. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Werewolf Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.28-4.8%-0.22-3.7%-0.31-5.3%0.010.1%0.010.1%
Usd Book Value Change Per Share-1.47-24.8%-0.06-1.1%-0.18-3.0%0.203.4%0.203.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.47-24.8%-0.06-1.1%-0.18-3.0%0.203.4%0.203.4%
Usd Price Per Share3.86-2.91-3.76-5.63-5.63-
Price to Earnings Ratio-3.44--3.73--2.98--3.27--3.27-
Price-to-Total Gains Ratio-2.63--35.39-32.92--8.94--8.94-
Price to Book Ratio1.48-1.01-1.22-1.59-1.59-
Price-to-Total Gains Ratio-2.63--35.39-32.92--8.94--8.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.9
Number of shares169
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.20
Usd Total Gains Per Share-0.060.20
Gains per Quarter (169 shares)-10.8433.88
Gains per Year (169 shares)-43.35135.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-43-530136126
20-87-960271262
30-130-1390407398
40-173-1820542534
50-217-2250678670
60-260-2680813806
70-303-3110949942
80-347-354010841078
90-390-397012201214
100-434-440013551350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.012.00.07.7%1.012.00.07.7%1.012.00.07.7%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%3.010.00.023.1%3.010.00.023.1%3.010.00.023.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%3.010.00.023.1%3.010.00.023.1%3.010.00.023.1%

Fundamentals of Werewolf Therapeutics Inc

About Werewolf Therapeutics Inc

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 10:55:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Werewolf Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Werewolf Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Werewolf Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -799.7% means that $-8.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Werewolf Therapeutics Inc:

  • The MRQ is -799.7%. The company is making a huge loss. -2
  • The TTM is -314.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-799.7%TTM-314.2%-485.5%
TTM-314.2%YOY-179.4%-134.8%
TTM-314.2%5Y-151.9%-162.3%
5Y-151.9%10Y-151.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-799.7%-199.6%-600.1%
TTM-314.2%-213.0%-101.2%
YOY-179.4%-279.3%+99.9%
5Y-151.9%-438.4%+286.5%
10Y-151.9%-605.5%+453.6%
1.1.2. Return on Assets

Shows how efficient Werewolf Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Werewolf Therapeutics Inc to the Biotechnology industry mean.
  • -6.9% Return on Assets means that Werewolf Therapeutics Inc generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Werewolf Therapeutics Inc:

  • The MRQ is -6.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.9%TTM-5.0%-1.8%
TTM-5.0%YOY-7.7%+2.6%
TTM-5.0%5Y-6.9%+1.9%
5Y-6.9%10Y-6.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.9%-13.5%+6.6%
TTM-5.0%-12.9%+7.9%
YOY-7.7%-11.8%+4.1%
5Y-6.9%-14.1%+7.2%
10Y-6.9%-16.0%+9.1%
1.1.3. Return on Equity

Shows how efficient Werewolf Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Werewolf Therapeutics Inc to the Biotechnology industry mean.
  • -10.8% Return on Equity means Werewolf Therapeutics Inc generated $-0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Werewolf Therapeutics Inc:

  • The MRQ is -10.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.8%TTM-7.9%-2.8%
TTM-7.9%YOY-9.8%+1.9%
TTM-7.9%5Y-7.5%-0.5%
5Y-7.5%10Y-7.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.8%-16.9%+6.1%
TTM-7.9%-16.1%+8.2%
YOY-9.8%-15.1%+5.3%
5Y-7.5%-19.9%+12.4%
10Y-7.5%-20.9%+13.4%

1.2. Operating Efficiency of Werewolf Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Werewolf Therapeutics Inc is operating .

  • Measures how much profit Werewolf Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Werewolf Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -863.6% means the company generated $-8.64  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Werewolf Therapeutics Inc:

  • The MRQ is -863.6%. The company is operating very inefficient. -2
  • The TTM is -346.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-863.6%TTM-346.6%-517.0%
TTM-346.6%YOY-200.0%-146.6%
TTM-346.6%5Y-168.2%-178.4%
5Y-168.2%10Y-168.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-863.6%-295.1%-568.5%
TTM-346.6%-225.8%-120.8%
YOY-200.0%-288.4%+88.4%
5Y-168.2%-477.4%+309.2%
10Y-168.2%-625.6%+457.4%
1.2.2. Operating Ratio

Measures how efficient Werewolf Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 9.64 means that the operating costs are $9.64 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Werewolf Therapeutics Inc:

  • The MRQ is 9.636. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.509. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ9.636TTM4.509+5.127
TTM4.509YOY3.627+0.881
TTM4.5095Y2.503+2.005
5Y2.50310Y2.5030.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.6363.090+6.546
TTM4.5093.264+1.245
YOY3.6273.783-0.156
5Y2.5035.679-3.176
10Y2.5037.894-5.391

1.3. Liquidity of Werewolf Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Werewolf Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.14 means the company has $7.14 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Werewolf Therapeutics Inc:

  • The MRQ is 7.141. The company is very able to pay all its short-term debts. +2
  • The TTM is 19.579. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.141TTM19.579-12.439
TTM19.579YOY7.390+12.189
TTM19.5795Y15.572+4.007
5Y15.57210Y15.5720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1413.914+3.227
TTM19.5794.220+15.359
YOY7.3905.388+2.002
5Y15.5726.045+9.527
10Y15.5726.406+9.166
1.3.2. Quick Ratio

Measures if Werewolf Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Werewolf Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 7.00 means the company can pay off $7.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Werewolf Therapeutics Inc:

  • The MRQ is 7.002. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 20.081. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.002TTM20.081-13.079
TTM20.081YOY7.197+12.884
TTM20.0815Y15.563+4.518
5Y15.56310Y15.5630.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0023.572+3.430
TTM20.0813.998+16.083
YOY7.1975.390+1.807
5Y15.5635.969+9.594
10Y15.5636.287+9.276

1.4. Solvency of Werewolf Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Werewolf Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Werewolf Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.36 means that Werewolf Therapeutics Inc assets are financed with 36.3% credit (debt) and the remaining percentage (100% - 36.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Werewolf Therapeutics Inc:

  • The MRQ is 0.363. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.279. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.363TTM0.279+0.084
TTM0.279YOY0.223+0.056
TTM0.2795Y0.501-0.222
5Y0.50110Y0.5010.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3630.336+0.027
TTM0.2790.334-0.055
YOY0.2230.269-0.046
5Y0.5010.366+0.135
10Y0.5010.390+0.111
1.4.2. Debt to Equity Ratio

Measures if Werewolf Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Werewolf Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 57.0% means that company has $0.57 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Werewolf Therapeutics Inc:

  • The MRQ is 0.570. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.441. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.570TTM0.441+0.129
TTM0.441YOY0.290+0.151
TTM0.4415Y0.246+0.195
5Y0.24610Y0.2460.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5700.382+0.188
TTM0.4410.396+0.045
YOY0.2900.335-0.045
5Y0.2460.434-0.188
10Y0.2460.465-0.219

2. Market Valuation of Werewolf Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Werewolf Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Werewolf Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -3.44 means the investor is paying $-3.44 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Werewolf Therapeutics Inc:

  • The EOD is -5.252. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.436. Based on the earnings, the company is expensive. -2
  • The TTM is -3.727. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.252MRQ-3.436-1.816
MRQ-3.436TTM-3.727+0.291
TTM-3.727YOY-2.982-0.744
TTM-3.7275Y-3.266-0.460
5Y-3.26610Y-3.2660.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.252-2.259-2.993
MRQ-3.436-2.569-0.867
TTM-3.727-2.664-1.063
YOY-2.982-4.120+1.138
5Y-3.266-6.258+2.992
10Y-3.266-6.171+2.905
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Werewolf Therapeutics Inc:

  • The EOD is -13.179. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.622. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.349. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.179MRQ-8.622-4.557
MRQ-8.622TTM-4.349-4.274
TTM-4.349YOY-9.742+5.394
TTM-4.3495Y-7.574+3.226
5Y-7.57410Y-7.5740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.179-2.924-10.255
MRQ-8.622-3.246-5.376
TTM-4.349-3.488-0.861
YOY-9.742-5.620-4.122
5Y-7.574-8.315+0.741
10Y-7.574-8.826+1.252
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Werewolf Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.48 means the investor is paying $1.48 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Werewolf Therapeutics Inc:

  • The EOD is 2.264. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.481. Based on the equity, the company is underpriced. +1
  • The TTM is 1.006. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.264MRQ1.481+0.783
MRQ1.481TTM1.006+0.475
TTM1.006YOY1.221-0.215
TTM1.0065Y1.590-0.585
5Y1.59010Y1.5900.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.2641.851+0.413
MRQ1.4812.090-0.609
TTM1.0062.095-1.089
YOY1.2212.844-1.623
5Y1.5903.466-1.876
10Y1.5903.815-2.225
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Werewolf Therapeutics Inc.

3.1. Institutions holding Werewolf Therapeutics Inc

Institutions are holding 73.881% of the shares of Werewolf Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31RA Capital Management, LLC14.37830.3705614488100
2023-12-31Mpm Asset Management, LLC10.02458.1262428417200
2023-12-31Adage Capital Partners Gp LLC7.09980.024330342552033658203.2445
2023-09-30Partner Fund Management LP5.98610.2579255828225439111.0418
2023-12-31MPM Oncology Impact Management LP5.58772.1566238801100
2023-12-31Bank of America Corp4.90460.0008209608156415736.8267
2023-12-31Rubric Capital Management LP4.52850.155193535700
2023-12-31Vanguard Group Inc2.04370.000187343832578759.4881
2023-12-31Sphera Funds Management Ltd.1.46670.389462681000
2023-12-31DC Funds, LP1.378427.342258910200
2023-09-30LAURION CAPITAL MANAGEMENT LP1.22350.006852290000
2023-12-31Millennium Management LLC1.03970.0007444359-22263-4.7711
2023-09-30Alyeska Investment Group, L.P.0.93080.005839780800
2023-12-31Geode Capital Management, LLC0.45470.00011943082005811.511
2023-12-31Two Sigma Advisers, LLC0.41490.00161773001773000
2023-09-30Schonfeld Strategic Advisors LLC0.40880.0029174724-151978-46.5188
2023-12-31Two Sigma Investments LLC0.34330.00131467361467360
2023-12-31Renaissance Technologies Corp0.25160.000610750662306137.8451
2023-12-31Bridgeway Capital Management, LLC0.19910.00785086-10425-10.915
2023-12-31State Street Corporation0.19530834683270064.4107
Total 62.8638.849826864584+3432427+12.8%

3.2. Funds holding Werewolf Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.32830.000356766500
2023-12-31HBM Healthcare Investments AG Ord1.07010.088445731000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.67390.00228800600
2024-02-29Fidelity Extended Market Index0.26380.002112733-546-0.482
2023-12-31Bridgeway Ultra-Small Company Market0.17920.159176586-13425-14.9148
2024-02-29Vifag 2002 SICAV0.16380.75717000000
2024-03-31BlackRock Extended Equity Market K0.13240.00255659236549182.3529
2024-03-28iShares Micro-Cap ETF0.10410.03144450500
2024-02-29Fidelity Total Market Index0.08570.00033661700
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.07540.0023221723581273.0547
2024-02-29Fidelity Series Total Market Index0.0650.000327795-1831-6.1804
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.06050.0022587518952273.7542
2024-03-29Avantis US Small Cap Equity ETF0.05670.01562422800
2023-09-30BlackRock Extended Mkt Composite0.05380.00042297400
2024-02-29DFA US Core Equity 2 I0.05120.00052187700
2024-02-29Fidelity Nasdaq Composite Index0.05050.0012159800
2024-03-29Dimensional US Small Cap ETF0.03940.00141685600
2023-12-31NT Ext Equity Mkt Idx Fd - L0.03710.00111584900
2023-12-31Northern Trust Extended Eq Market Idx0.03710.00111584900
2024-03-29Dimensional US Core Equity 2 ETF0.03330.00031423600
Total 4.56131.06881949368+63280+3.2%

3.3. Insider Transactions

Insiders are holding 6.759% of the shares of Werewolf Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-01-06Ra Capital Management, L.p.BUY18530002.21
2021-12-15Reid LeonardSELL300013.41
2021-05-04Bioventures 2014 L.p. MpmBUY12575916
2021-05-04Ra Capital Management, L.p.BUY171500016

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Werewolf Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.465-0.064-96%-0.178-88%0.200-831%0.200-831%
Book Value Per Share--2.6063.071-15%3.056-15%2.422+8%2.422+8%
Current Ratio--7.14119.579-64%7.390-3%15.572-54%15.572-54%
Debt To Asset Ratio--0.3630.279+30%0.223+63%0.501-27%0.501-27%
Debt To Equity Ratio--0.5700.441+29%0.290+97%0.246+132%0.246+132%
Dividend Per Share----0%-0%-0%-0%
Eps---0.281-0.219-22%-0.315+12%0.006-4718%0.006-4718%
Free Cash Flow Per Share---0.112-0.195+74%-0.259+131%-0.229+104%-0.229+104%
Free Cash Flow To Equity Per Share--0.1000.147-31%-0.166+265%0.232-57%0.232-57%
Gross Profit Margin--1.0381.010+3%1.000+4%1.003+4%1.003+4%
Intrinsic Value_10Y_max---6.516--------
Intrinsic Value_10Y_min---5.752--------
Intrinsic Value_1Y_max---0.903--------
Intrinsic Value_1Y_min---0.887--------
Intrinsic Value_3Y_max---2.522--------
Intrinsic Value_3Y_min---2.411--------
Intrinsic Value_5Y_max---3.912--------
Intrinsic Value_5Y_min---3.647--------
Market Cap252149480.000+35%164965592.000124472095.000+33%160798715.000+3%240676185.538-31%240676185.538-31%
Net Profit Margin---7.997-3.142-61%-1.794-78%-1.519-81%-1.519-81%
Operating Margin---8.636-3.466-60%-2.000-77%-1.682-81%-1.682-81%
Operating Ratio--9.6364.509+114%3.627+166%2.503+285%2.503+285%
Pb Ratio2.264+35%1.4811.006+47%1.221+21%1.590-7%1.590-7%
Pe Ratio-5.252-53%-3.436-3.727+8%-2.982-13%-3.266-5%-3.266-5%
Price Per Share5.900+35%3.8602.913+33%3.763+3%5.632-31%5.632-31%
Price To Free Cash Flow Ratio-13.179-53%-8.622-4.349-50%-9.742+13%-7.574-12%-7.574-12%
Price To Total Gains Ratio-4.027-53%-2.635-35.395+1243%32.923-108%-8.940+239%-8.940+239%
Quick Ratio--7.00220.081-65%7.197-3%15.563-55%15.563-55%
Return On Assets---0.069-0.050-27%-0.077+12%-0.069+1%-0.069+1%
Return On Equity---0.108-0.079-26%-0.098-9%-0.075-31%-0.075-31%
Total Gains Per Share---1.465-0.064-96%-0.178-88%0.200-831%0.200-831%
Usd Book Value--111374000.000131257500.000-15%130610750.000-15%103500153.846+8%103500153.846+8%
Usd Book Value Change Per Share---1.465-0.064-96%-0.178-88%0.200-831%0.200-831%
Usd Book Value Per Share--2.6063.071-15%3.056-15%2.422+8%2.422+8%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.281-0.219-22%-0.315+12%0.006-4718%0.006-4718%
Usd Free Cash Flow---4783000.000-8345250.000+74%-11051750.000+131%-9767692.308+104%-9767692.308+104%
Usd Free Cash Flow Per Share---0.112-0.195+74%-0.259+131%-0.229+104%-0.229+104%
Usd Free Cash Flow To Equity Per Share--0.1000.147-31%-0.166+265%0.232-57%0.232-57%
Usd Market Cap252149480.000+35%164965592.000124472095.000+33%160798715.000+3%240676185.538-31%240676185.538-31%
Usd Price Per Share5.900+35%3.8602.913+33%3.763+3%5.632-31%5.632-31%
Usd Profit---12003000.000-9175500.000-24%-12891000.000+7%-11203923.077-7%-11203923.077-7%
Usd Revenue--1501000.0004985750.000-70%4100250.000-63%2795692.308-46%2795692.308-46%
Usd Total Gains Per Share---1.465-0.064-96%-0.178-88%0.200-831%0.200-831%
 EOD+5 -3MRQTTM+9 -25YOY+14 -205Y+14 -2010Y+14 -20

4.2. Fundamental Score

Let's check the fundamental score of Werewolf Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.252
Price to Book Ratio (EOD)Between0-12.264
Net Profit Margin (MRQ)Greater than0-7.997
Operating Margin (MRQ)Greater than0-8.636
Quick Ratio (MRQ)Greater than17.002
Current Ratio (MRQ)Greater than17.141
Debt to Asset Ratio (MRQ)Less than10.363
Debt to Equity Ratio (MRQ)Less than10.570
Return on Equity (MRQ)Greater than0.15-0.108
Return on Assets (MRQ)Greater than0.05-0.069
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Werewolf Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose5.790
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets174,833
Total Liabilities63,459
Total Stockholder Equity111,374
 As reported
Total Liabilities 63,459
Total Stockholder Equity+ 111,374
Total Assets = 174,833

Assets

Total Assets174,833
Total Current Assets138,370
Long-term Assets36,463
Total Current Assets
Cash And Cash Equivalents 134,343
Net Receivables 1,350
Other Current Assets 2,677
Total Current Assets  (as reported)138,370
Total Current Assets  (calculated)138,370
+/-0
Long-term Assets
Property Plant Equipment 14,846
Long-term Assets Other 594
Long-term Assets  (as reported)36,463
Long-term Assets  (calculated)15,440
+/- 21,023

Liabilities & Shareholders' Equity

Total Current Liabilities19,378
Long-term Liabilities44,081
Total Stockholder Equity111,374
Total Current Liabilities
Short-term Debt 8,275
Short Long Term Debt 6,667
Accounts payable 1,336
Other Current Liabilities 8,860
Total Current Liabilities  (as reported)19,378
Total Current Liabilities  (calculated)25,138
+/- 5,760
Long-term Liabilities
Long term Debt 32,656
Capital Lease Obligations 12,600
Long-term Liabilities  (as reported)44,081
Long-term Liabilities  (calculated)45,256
+/- 1,175
Total Stockholder Equity
Common Stock4
Retained Earnings -344,073
Other Stockholders Equity 455,443
Total Stockholder Equity (as reported)111,374
Total Stockholder Equity (calculated)111,374
+/-0
Other
Capital Stock4
Cash and Short Term Investments 134,343
Common Stock Shares Outstanding 36,570
Current Deferred Revenue907
Liabilities and Stockholders Equity 174,833
Net Debt -82,420
Net Invested Capital 150,697
Net Working Capital 118,992
Property Plant and Equipment Gross 18,016
Short Long Term Debt Total 51,923



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
96,398
89,436
190,418
178,375
179,250
164,631
175,329
172,424
160,245
195,069
185,235
176,386
174,833
174,833176,386185,235195,069160,245172,424175,329164,631179,250178,375190,41889,43696,398000
   > Total Current Assets 
17,896
0
0
92,914
84,865
186,359
174,404
161,068
145,436
154,165
151,587
140,200
156,562
147,399
130,058
138,370
138,370130,058147,399156,562140,200151,587154,165145,436161,068174,404186,35984,86592,9140017,896
       Cash And Cash Equivalents 
-17,896
0
0
92,570
84,602
183,233
170,438
157,531
143,711
145,712
140,450
129,315
147,868
137,452
130,058
134,343
134,343130,058137,452147,868129,315140,450145,712143,711157,531170,438183,23384,60292,57000-17,896
       Short-term Investments 
35,792
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000035,792
       Net Receivables 
0
0
0
0
0
0
0
0
0
2,220
4,300
6,928
6,255
6,927
5,911
1,350
1,3505,9116,9276,2556,9284,3002,220000000000
       Other Current Assets 
0
0
0
344
263
3,126
3,966
3,537
1,725
6,233
6,837
3,957
2,439
2,812
3,079
2,677
2,6773,0792,8122,4393,9576,8376,2331,7253,5373,9663,126263344000
   > Long-term Assets 
0
0
0
3,484
4,571
4,059
3,971
18,182
19,195
21,164
20,837
20,045
38,507
37,836
37,128
36,463
36,46337,12837,83638,50720,04520,83721,16419,19518,1823,9714,0594,5713,484000
       Property Plant Equipment 
0
0
0
3,122
2,999
2,824
2,752
16,325
17,345
18,101
17,773
17,451
16,826
16,169
15,593
14,846
14,84615,59316,16916,82617,45117,77318,10117,34516,3252,7522,8242,9993,122000
       Other Assets 
0
0
0
0
1,572
1,235
1,219
1,857
1,850
3,063
3,064
10,885
0
21,667
9,200
0
09,20021,667010,8853,0643,0631,8501,8571,2191,2351,5720000
> Total Liabilities 
0
0
0
148,261
243,190
8,862
9,072
26,463
25,313
45,488
41,477
37,908
73,996
66,636
2,402
63,459
63,4592,40266,63673,99637,90841,47745,48825,31326,4639,0728,862243,190148,261000
   > Total Current Liabilities 
0
0
0
5,284
5,409
7,370
7,775
11,874
11,028
30,368
27,800
23,989
21,722
15,006
2,402
19,378
19,3782,40215,00621,72223,98927,80030,36811,02811,8747,7757,3705,4095,284000
       Short-term Debt 
0
0
0
677
699
721
744
1,072
1,458
1,871
2,020
2,084
2,146
1,970
3,272
8,275
8,2753,2721,9702,1462,0842,0201,8711,4581,072744721699677000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,667
6,667
6,6671,66700000000000000
       Accounts payable 
0
0
0
1,021
1,800
3,193
1,457
2,037
1,381
2,590
1,388
1,221
2,106
1,490
1,386
1,336
1,3361,3861,4902,1061,2211,3882,5901,3812,0371,4573,1931,8001,021000
       Other Current Liabilities 
0
0
0
3,586
20
3,456
5,574
8,765
8,189
14,090
13,934
14,152
12,153
9,940
-4,658
8,860
8,860-4,6589,94012,15314,15213,93414,0908,1898,7655,5743,456203,586000
   > Long-term Liabilities 
0
0
0
142,977
237,781
1,492
1,297
14,589
14,285
15,120
13,677
13,919
52,274
51,630
49,504
44,081
44,08149,50451,63052,27413,91913,67715,12014,28514,5891,2971,492237,781142,977000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
39,063
39,142
0
0
0039,14239,063000000000000
       Warrants
0
0
0
0
236,098
0
0
0
0
0
0
0
0
0
0
0
00000000000236,0980000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
1,445
534
0
0
783
0
0
00783005341,445000000000
       Deferred Long Term Liability 
0
0
0
0
1,274
27
11
0
0
0
0
0
0
0
0
0
00000000011271,2740000
> Total Stockholder Equity
9,769
0
0
-51,863
-153,754
181,556
169,303
152,787
139,318
129,841
130,947
122,337
121,073
118,599
112,443
111,374
111,374112,443118,599121,073122,337130,947129,841139,318152,787169,303181,556-153,754-51,863009,769
   Retained Earnings -344,073-332,070-323,785-318,687-306,705-294,775-282,832-268,238-252,895-235,026-221,268-153,756-51,865000
   Accumulated Other Comprehensive Income 000000000-178,375-190,418-354,8630000
   Capital Surplus 
0
0
0
0
0
402,822
404,327
405,680
407,554
412,671
425,719
429,039
439,757
442,381
0
0
00442,381439,757429,039425,719412,671407,554405,680404,327402,82200000
   Treasury Stock0000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue19,943
Cost of Revenue-1,764
Gross Profit18,17918,179
 
Operating Income (+$)
Gross Profit18,179
Operating Expense-58,682
Operating Income-40,503-40,503
 
Operating Expense (+$)
Research Development41,776
Selling General Administrative18,670
Selling And Marketing Expenses1,764
Operating Expense58,68262,210
 
Net Interest Income (+$)
Interest Income4,491
Interest Expense-3,139
Other Finance Cost-3,139
Net Interest Income4,491
 
Pretax Income (+$)
Operating Income-40,503
Net Interest Income4,491
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-37,368-43,638
EBIT - interestExpense = -43,642
-37,368
-34,229
Interest Expense3,139
Earnings Before Interest and Taxes (EBIT)-40,503-34,229
Earnings Before Interest and Taxes (EBITDA)-38,739
 
After tax Income (+$)
Income Before Tax-37,368
Tax Provision-0
Net Income From Continuing Ops-37,295-37,368
Net Income-37,368
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses60,446
Total Other Income/Expenses Net3,135-4,491
 

Technical Analysis of Werewolf Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Werewolf Therapeutics Inc. The general trend of Werewolf Therapeutics Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Werewolf Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Werewolf Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.74 < 8.1939.

The bearish price targets are: 3.89 > 3.86 > 3.35.

Tweet this
Werewolf Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Werewolf Therapeutics Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Werewolf Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartWerewolf Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Werewolf Therapeutics Inc. The current adx is .

Werewolf Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Relative Strength Index (RSI) ChartWerewolf Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Stochastic Oscillator ChartWerewolf Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Commodity Channel Index (CCI) ChartWerewolf Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartWerewolf Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Williams %R ChartWerewolf Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Average True Range (ATR) ChartWerewolf Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily On-Balance Volume (OBV) ChartWerewolf Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc Daily Money Flow Index (MFI) ChartWerewolf Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Werewolf Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Werewolf Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Werewolf Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose5.790
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Werewolf Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Werewolf Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Werewolf Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Werewolf Therapeutics Inc

I send you an email if I find something interesting about Werewolf Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Werewolf Therapeutics Inc.

Receive notifications about Werewolf Therapeutics Inc in your mailbox!